drugset / Trial / NCT03591874

Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease

NCT03591874

Phase 3 Terminated 59 enrolled Ocugen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluates the use of Brimonidine tartrate nanoemulsion eye drop solution in the treatment of ocular Graft Verses Host Disease (oGVHD). Two thirds of participants will receive Brimonidine and one third will receive ophthalmic buffered saline (placebo).

Timeline

Start
2018-12-23
Primary completion
2020-04-30
Completion
2020-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.18 %